Kythera Biopharmaceuticals Announces Presentation of Phase 2 Data on Novel Fat Reduction Drug at ASDS Meeting

(BUSINESS WIRE)-- MEDIA ADVISORY from KYTHERA Biopharmaceuticals: What: Presentation of Phase 2 Data on ATX-101, a First-in-Class, Novel, Injectable Drug For The Reduction of Localized Fat